According to the Zhitong Financial APP, on Wednesday, CVS Health (CVS.US) announced a spin-off while reporting its eighth consecutive quarter of earnings that exceeded expectations, along with 2027 profit guidance above Wall Street consensus. However, the market responded in complete opposition: overnight, the company’s stock plunged 12.5%.
This is an unusual valuation for a company that has just “outperformed expectations.” The market clearly isn’t focused on current profits—the real question is: why should these two businesses be worth more after the split?
According to the announcement, CVS will separate its retail pharmacy business from Aetna’s insurance and pharmacy benefit management (PBM) operations, effectively dismantling the $117 billion healthcare conglomerate built over many years. The transaction is expected to
Completion is expected in the first half of 2028, at which time CVS Health shareholders will hold shares in both companies.
This also means that, since acquiring Caremark PBM in 2006, CVS’s retail pharmacy business is returning to independent operations for the first time. Over the past two decades, the company has made a series of acquisitions, including the 2018 purchase of Aetna for $780
Acquired AnTai for US$1 billion.
The post-split structure has been finalized: Cigna Health will continue to be led by current CEO David Joyner, encompassing Express Scripts, Caremark, specialty pharmacies, and the healthcare services company Oak.
Street Health and Signify Health; Prem Shah, currently responsible for pharmacy and related businesses and healthcare delivery, will assume the role at CVS Pharmacy.
CEO, with business operations including MinuteClinic clinics, a mail-order pharmacy, and a service called Health100.
A consumer platform that helps patients manage their healthcare by leveraging data across insurance companies, healthcare providers, and pharmacies.
Numerically, this was an earnings report sufficient to support the stock price.
In the third quarter, the company earned $2.09 per share, significantly exceeding the analyst consensus of $1.65 according to LSEG—the eighth consecutive quarter it has surpassed Wall Street expectations. The company provided guidance for 2027
The adjusted earnings per share guidance for the year is at least $8.65, also exceeding the analyst consensus estimate of $8.53.
Management also emphasized improved fundamentals. Joyner stated that over the past two years, the company’s 9,000-pharmacy chain, Caremark,
The structural adjustment became possible only because both the pharmacy benefits management business and the Aetna insurance business have shown significant improvement. “All businesses are performing extremely well,” he said in the interview. “We now have the flexibility to make different decisions, something I couldn’t have done two years ago.”
He recalled that when he took over two years ago, the company anticipated a 5% decline in its pharmacy business; since then, CVS
Upgrade store technology to increase capacity and adjust the prescription drug reimbursement model to remain profitable while offering lower prices for both brand-name and generic drugs. For Aetna, previously due to its focus on individuals aged 65 and older,
Medicare Advantage plans experienced miscalculations in financial projections but have since been corrected.
Why doesn't this split lead to a valuation reevaluation?
First and most importantly: the split proposal lacks financial details, making it impossible for investors to model.
Barclays analyst Andrew Mok explicitly listed "lack of financial details surrounding the split" as investors' top concern. He reminded the market of a reference point: Cigna's acquisition of Caremark twenty years ago.
At the time, it claimed the transaction would generate at least $500 million in synergies. Following the same logic, a reverse split would similarly result in synergistic losses; however, this time, the company provided no quantitative guidance. Questions regarding how debt will be allocated between the two companies, how capital allocation policies will be structured, and the magnitude of one-time split costs—all critical factors affecting the valuation model’s denominator—remain unanswered.
Second, what is taken down may not necessarily be the part that has been criticized.
For years, industry consolidation has placed dual pressure on companies like CVS Health from regulators and consumers. Critics argue that these mergers create conflicts of interest across business lines and drive up U.S. healthcare spending—the highest in the world.
However, this spin-off separates the retail pharmacy stores, while the point of contention—the combination of insurance and PBM—remains within the same entity. Morningstar analyst Julie Utterback
The assessment is highly indicative: "In recent years, vertical integration in managed care organizations has come under criticism from both regulators and customers, and CVS has the largest exposure to this model in the industry." She believes, "Management likely believes it is better to take this step proactively now rather than wait for a law or legislative decision to force their hand."
In other words, this is a proactive move, not a cure. Regulatory risks have not disappeared due to the split; they have merely been relocated.
Third, splitting itself comes at a cost.
Two independent public companies mean two separate management teams, dual sets of compliance and investor relations costs, and the loss of existing cross-referral, centralized procurement bargaining power, and backend sharing capabilities. CVS
The pharmacy network with Aetna's insurance members and Caremark
The original prescription flows mutually supported each other; after the split, this "internal benefit" will become a transaction cost in external negotiations—yet the market currently has no data to assess whether this trade-off is worthwhile.
Fourth, while the guidance exceeds consensus, it is not superior to that of peers.
Kevin Gade, Chief Operating Officer of Bahl & Gaynor, noted that $8.65 for 2027
The annual guidance is not as attractive compared to peers: some competitors are more focused on government-led healthcare programs, and these businesses may receive greater political support next year following the Democrats' decisive win in congressional control during Tuesday's midterm elections. On the same day, political developments weakened
The relative value of this CVS guide.
Fifth, operational headwinds cannot be dismantled.
Pharmacy outlets still face payment pressures, competition from Amazon and other online pharmacies persists, and the trend toward prescription drug delivery has reduced in-store foot traffic that previously drove ancillary sales—this is the growing economic reality for large U.S. pharmacy chains. The insurance side is equally challenging: post-pandemic increases in consumer healthcare utilization, along with rising costs for Medicare and programs for low-income populations,
Medical costs for Medicaid, ACA plans, and commercial insurance lines are generally high.
The company’s own wording remains far from optimistic: while raising its adjusted profit forecast for 2026 to at least $8.20 per share, CVS Health expressed continued caution for the remainder of the year due to factors such as persistently high healthcare costs.
Sixth, the market has already heard this story once.
Reuters previously reported that Centene Corporation had in 2024
Throughout the year, the healthcare giant explored various options, including a potential split, as it navigated multiple challenges across its business segments. The expectation had already been priced in; when the plan was finally implemented, what was realized was merely “whether to split,” not “how much it would be worth after the split.”
Looking more closely, this split is the latest in a series of major corporate spin-offs this decade. As spin-offs shift from isolated cases to a trend, the narrative that “spin-offs unlock value” can no longer automatically command a premium—the market now demands evidence, and Cigna did not provide any.
The industry landscape is equally grim. After a prolonged sale process, competitor Walgreens sold its Boots pharmacy business last year and was itself acquired by private equity firm Sycamore.
Partners acquisition.
What you buy in the market is never already realized profits, but rather the future cash flow structure. Until questions about how debt is allocated, how capital is configured, and the extent of shared losses are answered, this split plan is merely a design blueprint—not yet a valuation. And
A 12.5% decline is the price investors have paid for this blank space.